| Patient group Active LN (NR/Relapse) Inactive LN (CR/PR) |
Parameter |
Baseline n=47 n=53 |
2 months n=29 n=71 |
4 months n=22 n=78 |
Active LN
Inactive LN |
Serum albumin
(35–50 g/L) |
37.78 ± 5.54
41.88 ± 3.59 |
39 ± 5
41.78 ± 3.20 |
37.5 ± 4.97
41.02 ± 5.82 |
| |
Inter group p value |
<0.001 |
<0.001 |
0.01 |
Active LN
Inactive LN |
Serum creatinine
(44 – 80 µmol/L) |
69 (IQR 33–252)
63 (IQR 41–158) |
72 (IQR 30–244)
65 (IQR 37–168) |
89.5 (IQR, 43–244)
63 (IQR 34–192) |
| |
Inter group p value |
0.29 |
0.36 |
0.004 |
Active LN
Inactive LN |
eGFR
(> 60 ml /min /1.73 m2) |
93.61 ± 46.01
99.75 ± 31.54 |
91 ± 49.16
98 ± 32.69 |
75.04 ± 39.95
98.35 ± 35 |
| |
Inter group p value |
0.43 |
0.53 |
0.009 |
Active LN
Inactive LN |
ESR |
38.5 (IQR 21–91)
33 (IQR 0–46) |
41 (IQR 22–92)
49 (IQR 10–103) |
32 (IQR 8–105)
36 (IQR 1–78) |
| |
Inter group p value |
0.37 |
0.86 |
0.36 |
Active LN
Inactive LN |
Anti-dsDNA Ab titers
(< 30 IU/dL) |
35.18 (IQR 1.73–195.97)
24.24 (IQR 0.81–279.21) |
30.23 (IQR 0.74–267.61)
14.37 (IQR 1.05–280) |
41.53 (IQR 2.07–291.62)
18.90 (IQR 0.95–262.21) |
| |
Inter group p value |
0.84 |
0.89 |
0.73 |
Active LN
Inactive LN |
Serum C3
(79 – 152 mg /dL) |
100.5 ± 36.39
109.62 ± 39.94 |
102.25 ± 40.53
106.37 ± 41.54 |
94.26 ± 26.67
104.16 ± 33.04 |
| |
Inter group p value |
0.24 |
0.32 |
0.21 |
Active LN
Inactive LN |
Serum C4
(16 – 38 mg /dL) |
21.46 ± 12.82
22.94 ± 11 |
21.14 ± 10.95
23.95 ± 13.69 |
22.81 ± 10.19
23.14 ± 9.48 |
| |
Inter group p value |
0.54 |
0.32 |
0.89 |
Active LN
Inactive LN |
Proteinuria (uPCI)
(< 20 mg/mmol creatinine) |
110 (IQR 10–510)
20 (IQR 10–50) |
130 (IQR 10–480)
20 (IQR 10–50) |
110 (IQR 10–510)
20 (IQR 10–30) |
| |
Inter group p value |
<0.001 |
<0.001 |
<0.001 |
Active LN
Inactive LN |
Urinary leucocytes/HPF×106 /L |
0 (0–20)
0 (0–5) |
0 (0––20)
0 (0–15) |
0 (0–20)
0 (0–10) |
| |
Inter group p value |
<0.001 |
0.30 |
0.007 |
Active LN
Inactive LN |
Urinary
RBC/HPF×106 /L |
0 (0–10)
0 (0––5) |
0 (0–20)
0 (0–15) |
0 (0–50)
0 (0–30) |
| |
Inter group p value |
<0.001 |
0.40 |
0.03 |
Active LN
Inactive LN |
uNGAL
(ng/ mg creatinine) |
195.80 (IQR 21.07–1,413)
83.66 (IQR 0–746.5) |
187.94 (IQR 58.57– 993)
100.80 (IQR 8.8 0–711) |
175 (IQR 40–840)
66.93 (IQR 10–605) |
| |
Inter group p value |
0.01 |
<0.001 |
<0.001 |
Active LN
Inactive LN |
SLEDAI-2K
(global: 0 – 105) |
8 (IQR 0–18)
2 (IQR 0–10) |
6 (IQR 0–18)
2 (IQR 0–12) |
8 (IQR 0–20)
2 (IQR 0–17) |
| |
Inter group p value |
<0.001 |
<0.001 |
<0.001 |
Active LN
Inactive LN |
SLEDAI-2K
(renal: 0 – 16) |
4 (IQR 0–16)
0 (IQR 0–3) |
4 (IQR 0–12)
0 (IQR 0–8) |
4 (IQR 0–16)
0 (IQR 0–12) |
| |
Inter group p value |
<0.001 |
<0.001 |
<0.001 |
Active LN
Inactive LN |
SLEDAI-2K
(extrarenal: 0 – 89) |
4 (IQR 0–12)
2 (IQR 0–10) |
2 (IQR 0–10)
2 (IQR 0–9) |
4 (IQR 0–12)
2 (IQR 0–8) |
| |
Inter group p value |
0.66 |
0.18 |
0.10 |
LN: Lupus Nephritis; eGFR: Estimated Glomerular Filtration Rate; ESR: Erythrocyte Sedimentation Rate; anti dsDNA: anti– double-stranded DNA antibody; C3: Complement 3; C4: Complement 4; uPCI: Urine Protein Creatinine Index; uNGAL: Urine Neutrophil Gelatinase-Associated Lipocalin; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2K